Newsroom Archives - Page 11 of 23 - Spectral Medical Inc

Spectral Medical Announces Tigris Clinical Trial Update

Enrollment momentum continues as Tigris Trial reaches 69 patients TORONTO, Canada – July 25, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today...

Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites

University of Alabama enrolls patient 65 after second day of opening for enrollment TORONTO, Canada – July 5, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and...

Spectral Medical Appoints Former FDA Director, Dr. David W. Feigal, Jr., to Its Board of Directors

TORONTO, Canada – June 27, 2023- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has appointed Dr. David W. Feigal, Jr., M.D., M.P.H.,...

Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Tigris trial enrollment at 64 patients Crude mortality results continue to exceed expectations TORONTO, Canada – June 20, 2023- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis...

Spectral Medical Provides Update on Favorable Tigris Clinical Trial Enrollment

Reports significant uptick in enrollment activities Tigris trial enrollment at 61 patients TORONTO, Ontario – May 30, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis...

Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment Activities

Tigris trial enrollment at 60 patients. TORONTO, Ontario – May 24, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today reported hosting an...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.